Resource Summary Report

Generated by NIF on Aug 12, 2026

LN-229

RRID:CVCL_0393
Type: Cell Line

Proper Citation

RRID:CVCL_0393

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0393

Proper Citation: RRID:CVCL_0393

Description: Cell line LN-229 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Glioblastoma

Defining Citation: PMID:7693337, PMID:8509230, PMID:9842975, PMID:10416987, PMID:14614447, PMID:14655754, PMID:16697959, PMID:17595512, PMID:19365568, PMID:20504876, PMID:21406405, PMID:22460905, PMID:22570425, PMID:25485619, PMID:25772239, PMID:25877200, PMID:25894527, PMID:25984343, PMID:26496030, PMID:26589293, PMID:27397505, PMID:27412690, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-229

Synonyms: LN 229, LN229, LNT-229

Cross References: BTO:BTO_0002004, CLO:CLO_0007363, EFO:EFO_0006637, MCCL:MCC:0000288, AddexBio:C0005017/4993, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2611, BioGRID_ORCS_Cell_line:929, BioSample:SAMN03471191, BioSample:SAMN03471692, BioSample:SAMN10987619, cancercelllines:CVCL_0393,

Cell_Model_Passport:SIDM00684, ChEMBL-Cells:CHEMBL4295402, ChEMBL-Targets:CHEMBL4296459, CLS:305043, Cosmic:849861, Cosmic:1746958, Cosmic:1995485, Cosmic:2302323, Cosmic:2367492, Cosmic:2491102, Cosmic:2516025, Cosmic:2580915, Cosmic-CLP:1240169, DepMap:ACH-000595, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240169, GEO:GSM101615, GEO:GSM101616, GEO:GSM326200, GEO:GSM397665, GEO:GSM397666, GEO:GSM481416, GEO:GSM887270, GEO:GSM888345, GEO:GSM1374621, GEO:GSM1670049, GEO:GSM2113428, GEO:GSM2113429, GEO:GSM2113430, GEO:GSM2113431, IARC_TP53:30212, LiGeA:CCLE_871, LINCS_LDP:LCL-1354, Lonza:1322, PharmacoDB:LN229_841_2019, PRIDE:PXD000589, PRIDE:PXD003790, PRIDE:PXD030304, Progenetix:CVCL_0393, PubChem_Cell_line:CVCL_0393, Ubigene:YC-A021, Wikidata:Q54902771

ID: CVCL_0393

Record Creation Time: 20220427T220730+0000

Record Last Update: 20260809T001542+0000

Ratings and Alerts

No rating or validation information has been found for LN-229.

No alerts have been found for LN-229.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 854 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Rivera-Caraballo KA, et al. (2026) Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. Cancer research, 86(5), 1232.

He M, et al. (2026) Feasibility and optimal imaging time window for intraperitoneal versus intravenous injection of a macrocyclic gadolinium-based contrast agent in mice. The Journal of international medical research, 54(6), 3000605261461956.

Fang C, et al. (2026) CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair. Genes & diseases, 13(5), 101948.

Mazewski C, et al. (2026) Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors. Cancers, 18(13).

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML. Cell metabolism, 38(6), 1113.

Sidhu RS, et al. (2026) Rap1b promotes glioma growth and stemness via regulation of Notch1 and VEGFR2 signaling pathways. Cellular signalling, 143, 112457.

Kempynck N, et al. (2026) CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species. Nature methods, 23(5), 946.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. Molecular oncology.

Daly J, et al. (2026) CRISPR activation screens map the genomic landscape of cancer glycome remodeling. Cell genomics, 6(4), 101139.

Su H, et al. (2026) Lipid Droplet-Localized Spindle Apparatus Coiled-Coil Protein 1 Regulates Lipid Droplet Distribution. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e11960.

Song J, et al. (2026) JOSD1 Deubiquitinates Twist1 and Facilitates Epithelial-Mesenchymal Transition in Glioblastoma. Cell biochemistry and function, 44(4), e70208.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. Molecular cell, 86(8), 1546.

Song X, et al. (2026) AI-driven network pharmacology and multi-omics validation identify KCNH2 as a prognostic biomarker and candidate therapeutic vulnerability of Acorus tatarinowii in glioblastoma. Frontiers in pharmacology, 17, 1811032.

Venkataramani P, et al. (2026) Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer. Cell chemical biology, 33(6), 810.

Sui M, et al. (2026) ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair. Molecular cancer research : MCR, 24(1), 7.

Meena D, et al. (2026) Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology. Journal of cellular physiology, 241(3), e70163.

Zhu M, et al. (2026) Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity. Biochemical pharmacology, 246, 117721.

Trautmann RK, et al. (2026) High-Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening. Macromolecular bioscience, 26(1), e00394.

Guo D, et al. (2026) Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion. Immunity, 59(7), 1811.

Yang M, et al. (2025) Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant

Glioblastoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e13632.